^
Association details:
| Biomarker: | KRAS mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | apitolisib (GDC-0980) (mTOR inhibitor, PI3K inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway
Excerpt:
Antitumor efficacy of GDC-0980 was investigated in vivo in 3 xenograft models in combination with DTX:...(ii) A549 is a NSCLC model that contains an activating K-RAS mutation and is negative for LKB1 protein expression,...the combination of GDC-0980 and DTX resulted in tumor regressions in all 3 xenograft model evaluated...
Secondary therapy:
docetaxel
DOI:
10.1158/1535-7163.MCT-11-0446
Source:
Title:
Phosphoinositide 3-Kinase (PI3K) Pathway Alterations Are Associated with Histologic Subtypes and Are Predictive of Sensitivity to PI3K Inhibitors in Lung Cancer Preclinical Models
Excerpt:
Treatment of NSCLC models with a KRAS mutation (A549) or concomitant KRAS and PIK3CA mutations (H460) with GDC-0941 resulted in 33% or 20% TGI, respectively (Fig. 4D). GDC-0980 had greater antitumor activity in these models, with 62% TGI in A549 xenografts and 43% in H460 xenografts...
DOI:
10.1158/1078-0432.CCR-12-2347
